Clinical study on Compound Xuelian Capsules combined with tofacitinib in treatment of rheumatoid arthritis
Objective To explore the clinical efficacy of Compound Xuelian Capsules combined with Tofacitinib Citrate Tablets in treatment of rheumatoid arthritis.Methods A total of 68 patients with rheumatoid arthritis admitted by Huangshan Shoukang Hospital from July 2022 to June 2024 were selected and divided into control group and treatment group according to the random number table,with 34 cases in each group.The control group patients took Tofacitinib citrate tablets,twice daily,1 tablets per time.On the basis of the control group,patients in the treatment group took Compound Xuelian Capsules,twice daily,2 capsules/time.The treatment efficacy,joint signs,pain level,disease activity,and serum indicators between the two groups were compared.Results Compared with the control group,the total effective rate of the treatment group was higher,and the difference between the groups was significant(P<0.05).The number of joint tenderness,swelling,and VAS score in both groups were significantly decreased(P<0.05),and the number of joint tenderness,swelling,and VAS score in the treatment group were significantly lower than those in the control group(P<0.05).The DAS28-ESR in both groups were significantly reduced(P<0.05).Compared with the control group,the DAS28-ESR score in the treatment group were smaller(P<0.05).The levels of RF,anti CCP antibodies,IL-8,IL-2R,and IL-1β in both groups after treatment were significantly reduced(P<0.05).The levels of RF,anti CCP antibodies,IL-8,IL-2R,and IL-1β in the treatment group were lower than those in the control group(P<0.05).Conclusion The combination of Compound Xuelian Capsules and Tofacitinib Citrate Tablets can improve the therapeutic effect of rheumatoid arthritis,further reduce joint pain and signs,lower disease activity,and alleviate inflammatory reactions.
Compound Xuelian CapsulesTofacitinib Citrate Tabletsrheumatoid arthritisnumber of joint tendernessnumber of swellingVAS scoreDAS28-ESR scoreRFanti CCP antibodyIL-8IL-2RIL-1β
万方数据
